J Korean Diabetes Assoc.  2007 Sep;31(5):429-434.

Prevalence of Diabetic Retinopathy in Diabetics Who are Positive for GAD Autoantibody

• Moon SJ
• Lee CH
• Moon JS
• Moon HJ
• Lee JE
• Chun KA
• Yoon JS
• Cho IH
• Won KC
• Lee HW

Abstract

BACKGROUND: Diabetic retinopathy is a leading cause of adult blindness. Some patients show early development and progression of diabetic retinopathy despite of apparently good glycemic control. This is suggesting the involvement of other contributing factors. Recent studies have shown that retinopathy and GAD autoantibody (GADA) show an inverse relationship immunologically. This study is designed to investigate the clinical manifestation of diabetes who are positive for GADA and the relationship between GADA and diabetic retinopathy.
METHODS
Type 1 diabetic patients & LADA patients who had visited Yeungnam university Medical Center from 1988 to 2005 were involved. We reviewed the pathologic and laboratory records of these patients and investigated the development of diabetic microvascular complications.
RESULTS
Compared with patients who had GADA negative diabetes, patients with GADA positive diabetes had lower prevalence of diabetic retinopathy (GADA negative subject: 25.8% vs. GADA positive subject: 9.6%, P < 0.05).
CONCLUSION
We confirmed that diabetic retinopathy and GADA showed an inverse relationship. It seems quite probable that GADA may contribute to the prevention of retinopathy. Further research should be needed concerning the effect of GADA on diabetic retinopathy.

Keyword

Diabetic retinopathy; GAD autoantibody; Late autoimmune diabetes in adults (LADA); Type 1 diabetes

MeSH Terms

Academic Medical Centers
Adult
Blindness
Diabetic Retinopathy*
Humans
Prevalence*

Figure

• 

  Fig. 1 Prevalence of diabetic retinopathy according to GADA. The prevalence of diabetic retinopathy is significantly lower in GADA positive patients group compared with GADA negative patients group.

Reference

1. Alaim M, Tim G, Desmond K, Michael O. Cause of blindness in the adult population of the republic of Ireland. Bre J Ophthalmol. 1998. 82:630–633.

2. Kuiper EJ, de Smet MD, Van Meurs JS, Tan HS, Tanck MW, Oliver N, Van Nieuwenhoven FA, Goldschmeding R, Schlingemann RO. Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye. Arch Ophthalmol. 2006. 10:1457–1462.

3. Sato T, Iwaki M, Shimogaito N, Wu X, Yamagishi S, Takeuchi M. TAGE(toxic AGEs) theory in diabetic complications. Curr Mol Med. 2006. 6(3):351–358.

4. Mimura T, Funatsu H, Uchigata Y, Kitano S. Development and progression of diabetic retinopathy in patients with Type 1 diabetes who are positive for GAD autoantibody. Diabet Med. 2004. 21:559–562.

5. Wasserfall CH, Atkinson MA. Autoantibody markers for the diagnosis and prediction of type 1 diabetes. Autoimmun Rev. 2006. 5:424–428.

6. Lizasoain I, Cardenas A, Hurtado O, Romera C, Mallolas J, Lorenzo P, Castillo J, Moro MA. Targets of Cytoprotection in Acute Ischemic Stroke: Present and Future. Cerebrovascular Disease. 2006. 21:1–8.

7. Ishikawa A, Ishiguro S, Tamai M. Changes in GABA metabolism in streptozotocin-induced diabetic rat retinas. Curr Eye Res. 1996. 15:63–71.

8. Connaughton VP, Behar TN, Massey SC. Immunocytochemical localization of excitatory and inhibitory neurotransmitters in the Zebrafish retina. Visual Neuroscience. 1999. 16:483–490.

9. Mimura T, Funatsu H, Uchigata Y, Kitano S. Relationship between human leukocyte antigen status and proliferative diabetic retinopathy in patients with younger-onset type 1 diabetes mellitus. Am J Ophthalmol. 2003. 135:844–848.

10. Mimura T, Funatsu H, Uchigata Y, Kitano S. Glutamic Acid Decarboxylase Autoantibody Prevalence and Association with HLA Genotype in Patients The younger-Onset Type 1 Diabetes and Proliferative Diabetic Retinopathy. Ophthalmology. 2005. 112:1904–1909.

11. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, Folli F, Richer-Olsen H, De Camilli P. Identification of the 64k autoantigen in insulin dependent diabetes as the GABA synthesizing enzyme glutamic acid decarboxylase. Nature. 1990. 347:151–156.

12. Pietropaolo M, Huttone JC, Eisenbarth GS. Protein tyrosine phosphatase-like proteins. Diabetes Care. 1997. 20:208–214.

13. Jerry P, Christiane S, Harvey Chiu, Amit G, Barbara M. Is Latent Autoimmune Diabetes in Adult Distinct From Type 1 Diabetes or Just Type 1 Diabetes at an Older Age? Diabetes. 2005. 54:S62–S67.

14. Cifkova R, Erdine S, Fagard R, Farsang C, heagerty AM, Kiowski W, Kjeldsen S, Luscher T, Mallion JM, Manica G, Poulter N, Rahn KH, Rodicio JL, Ruilope LM. Practice Guidelines For Primary Care Physicians:2003 ESH/ESC Hypertensio. Guidelines. 2003. 21:1011–1053.

15. Sarah W, Gojka R, Anders G, Richard S, Hilary K. Global prevalence of diabetes. Diabetes Care. 2004. 27:1047–1053.

16. Antonetti David A, Barber Alistair J, Bronson Sarah K. Diabetic Retinopathy: Seeing beyond Glucose-induced Microvascular Disease. Diabetes. 2006. 55:2401–2411.

17. Agardh D, agardh E, Landin-Olssen M, Gaur LK, Lernmark A. Inverse relation-ship between GAD65 antibody levels and severe retinopathy in younger type 1 diabetic patients. Diabetes Res Clin Pract. 1998. 40:9–14.

18. Kobayashi N, Ishiguro S, Tomita H, Nishikawa S, Tamai M. Changes of GABA metabolic enzymes in acute retinal ischemia. Exp Eye Res. 1999. 69:91–96.

19. Frayser R, buse MG. branched chain amino acid metabolism in the retina of diabetic rats. Diabetologia. 1978. 14:171–176.

20. Perry TL, Hansen S, Gandham SS. Post-mortem changes of amino compounds in human and rat brain. J Neurochem. 1981. 36:406–412.

21. Hall ZW, Kravitz EA. The metabolism of γ-aminobutyric acid(GABA) in the lobster nervous system-I. J Neurochem. 1967. 14:45–54.

22. Hermitte L, Atlan-Gepner C, Mattei C, Dufayet D, Jannot MF, Christofilis MA, Nervi S, Vialettes B. Diverging evolustion of anti-GAD and anti-IA-2 antibodies in long-standing diabetes mellitus as a function of age at onset:no association with complications. Diabet Med. 1998. 15:586–591.

23. Viktoira G, Niels E, Mark P. Autoantibodies to Autonomic Nerves Associated with Cardiac and Peripheral Autonomic Neuropathy. Diabetes Care. 2005. 28:1959–1964.

24. Serjeantson SW, Kohonen-Corish MRJ, Rowley MJ. Antibodies to glutamic acid decarboxylase are associated with HLA-DR genotypes in both Australian and Asian with type 1 diabetes mellitus. Diabetologia. 1992. 35:996–1001.

25. Eberhardt MS, Wagener DK, Orchard TJ. HLA heterogeneity of insulin dependent diabetes mellitus at diagnosis. Diabetes. 1985. 34:1247–1252.

26. Ludvigsson J, Samuelsson U, Beauforts C. HLA-DR3 is associated with more slowly progressive form of type 1 diabetes. Diabetologia. 1986. 29:207–210.

27. Genovese S, Sakamaki T, Konda S. Association of IA-2 autoantibodies with HLADR4 phenotypes in IDDM. Diabetologia. 1996. 39:1223–1226.

28. Kahn HA, Bradley RF. Prevalence of diabetic retinopathy. Age, sex, and duration of diabetes. Br J Ophthalmol. 1975. 59:345–349.

29. Matsuda M, Ohguro N, Ishimoto I, Fukuda M. Relationship of corneal endothelial morphology to diabetic retinopathy, duration of diabetes and glycemic control. Jpn J Ophthalmol. 1990. 34:53–56.

30. Gillow JT, Gibson JM, Dodson PM. Hypertension and diabetic retinopathy-what's the story? Br J Ophthalmol. 1999. 83:1083–1087.

31. Klein R, Moss SE, Davis MD, DeMets DL. Wisconsin Epidemiologic Study of Diabetic Retinopahty. XII. Relationship of C-peptide and diabetic retinopathy. Diabetes. 1990. 39:1445–1450.

32. Biesenbach G, Auinger M, Clodi M, Prischl F, Kramar R. Prevalence of LADA and frequency of GAD antibodies in diagetic patients with end-stage renal disease and dialysis treatment in Austria. Neprol Dial Transplant. 2005. 20:559–565.